ACC

ACC 2025. Tirzepatide improved HF symptoms and renal function in patients with obesity-related HFpEF, regardless of CKD status, according to new findings from the SUMMIT trial.

The study that led to an historic expanded label for bempedoic acid must be followed by more like it, said Steven Nissen, MD. There is much more to do.

Statin intolerance is a "vexing" problem for primary care clinicians and specialists alike. Bempedoic acid fills a distinct need in that tool box.

The CLEAR Outcomes PI explains the patient selection approach for bempedoic acid, now approved to reduce risk of CV events in addition to lowering LDL-C.

ACC.24: Adults with a history of CVD consumed more than double the recommended daily sodium amount, reported researchers.

ACC.24: Michael Koren, MD, highlights how the nonstatin lipid-lowering medication's mechanism of action against PCSK9 differs from others in the category.

ACC.24: The primary investigator of the VICTORION-INITIATE study explains why new strategies are needed to accelerate LDL-C lowering in high-risk individuals.

ACC. 24: A structured, systematic approach to lipid-lowering therapy in secondary prevention is needed to ensure targets are met and met swiftly, said researchers.

ACC.24: Data showed that individuals who used e-cigarettes were approximately 19% more likely to develop heart failure compared with those who had never vaped.

ACC.24: Loss of estrogen's cardioprotective effect could account for the 2-fold greater increase in CAC score seen among postmenopausal women compared with men.

ACC.24: Data showed that participants with ADHD who were prescribed stimulants were 17% more likely to develop cardiomyopathy at 1 year.

ACC.24: Icosapent ethyl was associated with reduced rate of MACE at all baseline levels of Lp(a) in participants with elevated TG and at high risk for CVD.

ACC.24: Data from an analysis of the CLEAR Outcomes trial showed bempedoic acid was well-tolerated and reduced CV events in Hispanic/Latinx and non-Hispanic/Latinx participants.

CLEAR Outcomes PI Steven Nissen, MD, links findings from the pivotal trial with labeling updates that make bempedoic acid the only nonstatin agent approved to reduce CV risk.

ACC.24: Findings showed a disproportionate distribution of CAC screening that favors White, educated, affluent, English-speaking individuals.

ACC.2024: In a cohort of people at high risk of ASCVD, three-quarters achieved target LDL-C levels at 6 months and 12 months while using a remote algorithm-directed program.

ACC 2023. Electronic nudges highlighting the potential cardiovascular benefits of flu vaccination led to a modest uptake in vaccination rates among older adults in Denmark, according to results of the NUDGE-FLU trial.

ACC2023. Risk for MACE was nearly 7-fold higher in participants on a keto diet whose LDL-C was already high compared with those on a standard diet with LDL-C in a normal range.

ACC 2023. In the CLEAR Outcomes trial, bempedoic acid reduced risk for major CV events by 13% compared with placebo in patients who had, or were at high risk for, CVD.

ACC2023. For high-risk T2D patients not receiving optimal treatment for hyperlipidemia, hypertension, or hyperglycemia, intensive, multidisciplinary training for clinic staff could shift practice.

ACC 2023. The Mediterranean diet has a beneficial effect on the primary prevention of cardiovascular disease and death in women, according to new analysis.

ACC 2023. Results from a 2-decade study showed that all-cause mortality rates were significantly higher in patients with obesity with uncontrolled HTN compared to those without HTN.

ACC 2023. In an analysis of patients with heart failure, never having been married was associated with worse survival compared with having been married.

ACC 2023. A large study found increased risk for MI regardless of age and detected particularly heightened risk among women and persons with diabetes who have insomnia.

ACC 2023. New study found cognitive behavioral therapy delivered via mobile app significantly reduced HbA1c and need for antihyperglycemic intensification compared to use of a control app.

ACC 2023. Daily marijuana users were 34% more likely to have coronary artery disease than never-users, according to new research.

Dylan Steen, MD talks about several SuperWIN results that caught him happily by surprise and suggest plenty of room for follow-up research.

SuperWIN trial findings suggest the future of successful health care depends on harnessing familiar, community- based resources to maintain health and deliver care.

Coprincipal investigator Steen highlights the first-of-its kind study and the findings—local in-store dietitian counseling/feedback, nutrition education, and online shopping savvy improve food choices, health metrics.

ACC 2022: Use of antihypertensive therapy in pregnant women was associated with better pregnancy outcomes, such as preeclampsia and fetal or neonatal death.